

RealRate

PHARMACEUTICAL 2017

ALDER BIOPHARMACEUTICALS INC Rank 33 of 292







PHARMACEUTICAL 2017

## RealRate

## ALDER BIOPHARMACEUTICALS INC Rank 33 of 292

The relative strengths and weaknesses of ALDER BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALDER BIOPHARMACEUTICALS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 105% points. The greatest weakness of ALDER BIOPHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 231%, being 228% points above the market average of 2.9%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 393,183              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 25,890               |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 8,895                |
| Other Compr. Net Income                     | 453                  |
| Other Expenses                              | 113                  |
| Other Liabilities                           | 481                  |
| Other Net Income                            | 2,767                |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 7,076                |
| Research and Development                    | 132,760              |
| Selling, General and Administrative Expense | 26,148               |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 409,154              |
| Liabilities              | 26,371               |
| Expenses                 | 159,021              |
| Revenues                 | 0                    |
| Stockholders Equity      | 382,783              |
| Net Income               | -156,254             |
| Comprehensive Net Income | -156,028             |
| Economic Capital Ratio   | 231%                 |

